11-78436813-A-G
Variant summary
Our verdict is Uncertain significance. Variant got 5 ACMG points: 5P and 0B. PM2PP3_ModeratePP5
The NM_024678.6(NARS2):āc.1291T>Cā(p.Tyr431His) variant causes a missense, splice region change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000955 in 1,613,352 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 3/3 splice prediction tools predict no significant impact on normal splicing. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_024678.6 missense, splice_region
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 5 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
NARS2 | NM_024678.6 | c.1291T>C | p.Tyr431His | missense_variant, splice_region_variant | 14/14 | ENST00000281038.10 | NP_078954.4 | |
NARS2 | NM_001243251.2 | c.610T>C | p.Tyr204His | missense_variant, splice_region_variant | 14/14 | NP_001230180.1 | ||
NARS2 | XM_011545253.3 | c.1264T>C | p.Tyr422His | missense_variant, splice_region_variant | 13/13 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
NARS2 | ENST00000281038.10 | c.1291T>C | p.Tyr431His | missense_variant, splice_region_variant | 14/14 | 1 | NM_024678.6 | ENSP00000281038.5 |
Frequencies
GnomAD3 genomes AF: 0.0000394 AC: 6AN: 152272Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000440 AC: 11AN: 249796Hom.: 0 AF XY: 0.0000444 AC XY: 6AN XY: 135126
GnomAD4 exome AF: 0.000101 AC: 148AN: 1461080Hom.: 0 Cov.: 31 AF XY: 0.0000922 AC XY: 67AN XY: 726870
GnomAD4 genome AF: 0.0000394 AC: 6AN: 152272Hom.: 0 Cov.: 32 AF XY: 0.0000269 AC XY: 2AN XY: 74402
ClinVar
Submissions by phenotype
not provided Pathogenic:1Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Nov 24, 2023 | This sequence change replaces tyrosine, which is neutral and polar, with histidine, which is basic and polar, at codon 431 of the NARS2 protein (p.Tyr431His). This variant is present in population databases (rs370150532, gnomAD 0.01%). This variant has not been reported in the literature in individuals affected with NARS2-related conditions. ClinVar contains an entry for this variant (Variation ID: 1297024). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Likely pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Nov 04, 2024 | Reported in the single heterozygous state as a rare variant from a cohort of individuals with colorectal cancer (PMID: 26901136); Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 26901136) - |
NARS2-related disorder Uncertain:1
Uncertain significance, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | May 10, 2024 | The NARS2 c.1291T>C variant is predicted to result in the amino acid substitution p.Tyr431His. This variant has been observed in an individual with an early-onset colorectal cancer (Table S3, de Voer et al. 2016. PubMed ID: 26901136). This variant is reported in 0.0094% of alleles in individuals of European (Non-Finnish) descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. - |
Combined oxidative phosphorylation defect type 24 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Institute of Human Genetics, University of Leipzig Medical Center | Jul 16, 2021 | The variant was identified in a compound heterozygous state with the variant c.167A>G, p.(Gln56Arg) in a patient with a phenotype that was compatible with a NARS2-related disorder (epileptic encephalopathy). - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at